Lumiracoxib


Concise Prescribing Info
Indications/Uses
Osteoarthritis of the knee.
Dosage/Direction for Use
Adult : PO 100 mg once daily. Max: 400 mg/day.
Dosage Details
Oral
Osteoarthritis of the knee
Adult: 100 mg once daily. Max: 400 mg/day.
Renal Impairment
Moderate to severe (CrCl <50 mL/min): Contraindicated.
Hepatic Impairment
Contraindicated.
Administration
May be taken with or without food.
Contraindications
Patient w/ ischaemic heart disease, cerebrovascular disease, or peripheral arterial disease. Patient w/ history of drug-induced increases in transaminase values >3 times the upper limit of normal (ULN) or in those taking other drugs known to cause clinically significant hepatotoxicity. Patient w/ inflammatory bowel disease, moderate to severe heart failure (NYHA class II-IV). Concomitant use w/ drugs known to cause hepatotoxicity. Hepatic impairment. Moderate to severe renal impairment (CrCl <50 mL/min).
Special Precautions
Dehydrated patient; patient w/ significant risk factors for CV disease e.g. HTN, hyperlipidaemia, and DM.
Adverse Reactions
Anorexia, nausea, vomiting, abdominal pain, fatigue, dark urine and jaundice.
Potentially Fatal: Severe hepatotoxicity, upper GI ulceration and bleeding.
MonitoringParameters
LFTs should be monitored mthly. Monitor renal function at the beginning and during treatment.
Drug Interactions
May decrease the clearance of CYP2C9 substrates (e.g. phenytoin, warfarin). May increase anticoagulant effect of warfarin, acenocoumarol, anisindione and dicoumarol. Concomitant use w/ telmisartan may increase the risk of acute renal failure and hyperkalaemia. Tolbutamide may decrease the metabolism and clearance of lumiracoxib. May antagonise the antihypertensive effect of timolol. May increase lithium serum levels. May decrease antihypertensive effect of trandolapril.
Potentially Fatal: Increased risk of hepatotoxicity w/ drugs known to cause hepatotoxicity.
Action
Description: Lumiracoxib is an NSAID and a selective inhibitor of cyclo-oxygenase-2 (COX-2). Its action is due to inhibition of prostaglandin synthesis via inhibition of COX-2.
Pharmacokinetics:
Absorption: Rapidly absorbed. Absolute bioavailability: 74%. Time to peak plasma concentration: Approx 2 hr.
Distribution: Plasma protein binding: ≥98%.
Metabolism: Undergoes extensive hepatic metabolism via glucurosyltransferase and CYP450 isoenzymes. Major metabolites include 4'-hydroxy-lumiracoxib (active as COX-2 inhibitor), 5-carboxy-lumiracoxib, and 4'-hydroxy-5-carboxy-lumiracoxib.
Excretion: Via urine (54%) and faeces (approx 43%); approx 5% as unchanged drug. Plasma half-life: Approx 4 hr.
References
Buckingham R (ed). Lumiracoxib. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/03/2014.

Lumiracoxib (Prexige): Suspension of Marketing Authorisations. Medicines & Healthcare products Regulatory Agency. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency. Accessed 10/03/2014.

Disclaimer: This information is independently developed by MIMS based on Lumiracoxib from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in